daunorubicin has been researched along with s 16020-2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvord, WG; Gray-Goodrich, M; Jeffers, M; Kohlhagen, G; Koo, HM; McWilliams, MJ; Monks, A; Paull, KD; Pommier, Y; Vaigro-Wolff, A; Vande Woude, GF | 1 |
| Koo, HM; Vande Woude, GF | 1 |
2 other study(ies) available for daunorubicin and s 16020-2
| Article | Year |
|---|---|
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Colonic Neoplasms; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, ras; Humans; Mutation; Phenotype; Pyridines; Topoisomerase II Inhibitors; Transfection; Tumor Cells, Cultured | 1999 |
Re: The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carbazoles; Daunorubicin; Enzyme Inhibitors; Genes, ras; Humans; Neoplasms; Pyridines; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |